Peptide–Drug Conjugates as Next-Generation Therapeutics: Exploring the Potential and Clinical Progress
Peptide–drug conjugates (PDCs) have emerged as a next-generation therapeutic platform, combining the target specificity of peptides with the pharmacological potency of small-molecule drugs. As an evolution beyond antibody–drug conjugates (ADCs), PDCs offer distinct advantages, including enhanced cel...
Saved in:
| Main Authors: | Krishna Jadhav, Ashwin Abhang, Eknath B. Kole, Dipak Gadade, Apurva Dusane, Aditya Iyer, Ankur Sharma, Saroj Kumar Rout, Amol D. Gholap, Jitendra Naik, Rahul K. Verma, Satish Rojekar |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Bioengineering |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2306-5354/12/5/481 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Current Status of the Application of Antimicrobial Peptides and Their Conjugated Derivatives
by: Marcel·lí del Olmo, et al.
Published: (2025-07-01) -
Linker-GPT: design of Antibody-drug conjugates linkers with molecular generators and reinforcement learning
by: An Su, et al.
Published: (2025-07-01) -
Radionuclide Drug Conjugates: China's 15-Year Research and Development Process and Latest Policy Support
by: LIU dan, et al.
Published: (2024-09-01) -
Synergistic action between peptide-neomycin conjugates and polymyxin B against multidrug-resistant gram-negative pathogens
by: Sandra Story, et al.
Published: (2025-08-01) -
In silico decrypting of the bystander effect in antibody–drug conjugates for breast cancer therapy
by: Víctor L. Cruz, et al.
Published: (2025-08-01)